Toronto, Canada

Johanna Rommens

USPTO Granted Patents = 39 


Average Co-Inventor Count = 3.8

ph-index = 10

Forward Citations = 342(Granted Patents)


Location History:

  • Willowdale, CA (1996 - 2006)
  • Ontario, CA (2010)
  • Toronto, CA (1998 - 2022)

Company Filing History:

goldMedal11 out of 165 
 
The Hospital for Sick Children
 patents
silverMedal10 out of 36 
 
Hsc Research and Development Limited Partnership
 patents
bronzeMedal7 out of 15,528 
 
University of California
 patents
47 out of 497 
 
University of Toronto
 patents
55 out of 15 
 
Hsc Research Development Corporation
 patents
63 out of 116 
 
Myriad Genetics, Inc.
 patents
73 out of 80 
 
Endorecherche, Inc.
 patents
83 out of 2,623 
 
University of Pennsylvania
 patents
92 out of 3,390 
 
University of Michigan
 patents
101 out of 8 
 
The Board of Regents Acting for and on Behalf of the University of
 patents
111 out of 1 
 
Research and Development Limited Partnership
 patent
121 out of 1 
 
Hsc Research & Development Limited Parntership
 patent
131 out of 1 
 
Myriad Genectics, Inc.
 patent
141 out of 1 
 
Hsc Reseach & Development Limited Partnership
 patent
151 out of 1 
 
The Hospital for Sick Children, Hsc Research and Development Limited
 patent
161 out of 934 
 
The University of British Columbia
 patents
171 out of 5 
 
Hsc Research and Development Limited
 patents
181 out of 1,650 
 
University of Utah Research Foundation
 patents
199 out of 832,912 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2022

Loading Chart...
Loading Chart...
39 patents (USPTO):Explore Patents

Title: The Innovative Work of Inventor Johanna Rommens

Introduction:

Johanna Rommens is a renowned inventor based in Toronto, CA, known for her pioneering work in the field of genetic modifications associated with various diseases. With a total of 19 patents to her name, Rommens has significantly contributed to advancements in personalized medicine and treatment methodologies.

Latest Patents:

1. Modifiers of CFTR-directed therapy: Rommens' patent revolves around a genetic modifier of cystic fibrosis (CF), which can predict the effectiveness of CFTR-directed therapy. By identifying specific SNPs in non-coding regions of SLC26A9, correlations with CF lung disease severity and patient response to therapies like Ivacaftor have been established. This innovation provides a breakthrough in predicting treatment efficacy and patient selection for CFTR-directed therapeutics.

2. Genes from 20q13 amplicon and their uses: This patent focuses on cDNA sequences from a region on chromosome 20 linked to diseases. The identified sequences are instrumental in detecting chromosomal abnormalities associated with various disorders and offer potential for disease treatment.

Career Highlights:

Johanna Rommens has made significant contributions working at prestigious institutions such as The Hospital for Sick Children and the University of California. Her career highlights include groundbreaking research in genetic modifiers and disease-associated gene sequences, leading to the development of novel treatment methodologies for complex diseases.

Collaborations:

Throughout her career, Rommens has collaborated with esteemed professionals in the field, including Joe W Gray and Colin Conrad Collins. These collaborations have fostered innovative research endeavors and propelled advancements in the field of genetics and personalized medicine.

Conclusion:

Inventor Johanna Rommens' dedication to advancements in genetic modifiers and disease treatment strategies has left a lasting impact on the field of personalized medicine. Her patents and collaborations stand as a testament to her innovative spirit and commitment to improving healthcare outcomes for individuals affected by complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…